2021
The effect of short radiation treatment breaks on chemo‐radiotherapy for oropharyngeal cancers
Rybkin A, Kang JJ, Lee A, Kitpanit S, Fan M, Mohamed N, Cartano O, Zakeri K, Gelblum D, Sherman E, Dunn L, Boyle J, Wong R, Chen L, Yu Y, McBride SM, Tsai CJ, Riaz N, Lee NY. The effect of short radiation treatment breaks on chemo‐radiotherapy for oropharyngeal cancers. Head & Neck 2021, 43: 3796-3809. PMID: 34585792, PMCID: PMC9414892, DOI: 10.1002/hed.26879.Peer-Reviewed Original ResearchConceptsRadiation treatment breaksOropharyngeal squamous cell carcinomaOverall treatment timeTreatment breaksClinical outcomesDefinitive concurrent chemoradiotherapySquamous cell carcinomaConcurrent chemoradiotherapyOPSCC patientsOropharyngeal cancerDisease failureCell carcinomaNeck cancerCancer recurrenceConsecutive cohortMultivariate analysisSignificant associationPatientsCancerFurther investigationProlongationDaysOutcomesNumerous studiesChemoradiotherapy
2019
A retrospective analysis of cisplatin dosing strategies when used with radiation on outcomes in head and neck squamous cell carcinoma of the oropharynx.
Tchekmedyian V, Ho A, Dunn L, Fetten J, Pfister D, Lobaugh S, Zhang Z, Kang J, Chen L, Riaz N, McBride S, Yu Y, Tsai C, Lee N, Sherman E. A retrospective analysis of cisplatin dosing strategies when used with radiation on outcomes in head and neck squamous cell carcinoma of the oropharynx. Journal Of Clinical Oncology 2019, 37: 6079-6079. DOI: 10.1200/jco.2019.37.15_suppl.6079.Peer-Reviewed Original ResearchHPV/p16 statusOverall survivalRetrospective analysisTotal doseT stageP16 statusMultivariate Cox proportional hazards modelMultivariate analysisMedian f/uCox proportional hazards regressionCox proportional hazards modelNeck squamous cell carcinomaHPV/p16Start of RTProportional hazards regressionSquamous cell carcinomaSplit-dose administrationProportional hazards modelCI dosingPrimary CRTInduction chemotherapyCRT outcomesDistant failureProspective trialMedian age
2018
First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology
Kang JJ, Reiter RE, Steinberg ML, King CR. First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology. European Urology Oncology 2018, 1: 378-385. PMID: 31158076, DOI: 10.1016/j.euo.2018.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedFollow-Up StudiesHumansMaleMargins of ExcisionMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingNeoplasm, ResidualPostoperative PeriodPrognosisProstatectomyProstate-Specific AntigenProstatic NeoplasmsRadiotherapy, AdjuvantRetrospective StudiesRisk FactorsSalvage TherapySurvival AnalysisConceptsBone metastasis-free survivalProstate cancer-specific survivalUltrasensitive prostate specific antigenOverall survivalBiochemical relapseProstate-specific antigenRadical prostatectomyMultivariate analysisProstate-specific antigen levelImmediate adjuvant therapyOccult prostate cancerOccult systemic diseaseCancer-specific survivalEarly salvage radiotherapyHigh-risk diseaseKaplan-Meier methodTraditional risk factorsMetastasis-free survivalPrediction of outcomeProstate cancer pathologyAdjuvant therapySalvage radiotherapyHormone therapyIndependent predictorsStudy endpoint
2014
Ultrasensitive Prostate Specific Antigen after Prostatectomy Reliably Identifies Patients Requiring Postoperative Radiotherapy
Kang JJ, Reiter RE, Steinberg ML, King CR. Ultrasensitive Prostate Specific Antigen after Prostatectomy Reliably Identifies Patients Requiring Postoperative Radiotherapy. Journal Of Urology 2014, 193: 1532-1538. PMID: 25463990, PMCID: PMC4527538, DOI: 10.1016/j.juro.2014.11.017.Peer-Reviewed Original ResearchConceptsUltrasensitive prostate specific antigenProstate-specific antigenInitial prostate-specific antigenPostoperative prostate-specific antigenBiochemical relapseSpecific antigenHigh riskRadical prostatectomyPostoperative radiotherapyT stageGleason gradeMultivariate analysisProstate-specific antigen (PSA) recurrenceEventual biochemical failureSpecific antigen recurrenceCox multivariate analysisTraditional risk factorsConventional prostate specific antigenBiochemical failureIdentifies patientsMedian followupMargin statusPathology findingsKaplan-MeierPositive margins